Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HCTI vs GRML: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRML Captures Overall Composite Edge (56.8 HOLD vs 36.5 SELL), While HCTI Leads 5–1 on Growth & Valuation Pillars

GRML Overall Winner 6-Pillar Tally: HCTI 5 – 1 GRML Matrix Metrics: HCTI 6 – 2 GRML

As of Nov 16, 2026, GRML (GRML) captures the overall head-to-head institutional edge over Healthcare Triangle, Inc. (HCTI) on higher Unified Composite conviction (56.8/100 HOLD vs. 36.5/100 SELL) after splitting the core matrix 2–6 (led by Options & Positioning), while HCTI wins 5–1 across the 6-pillar growth and valuation breakdown. HCTI trades at $3.42 (N/M Forward P/E, -57.4% operating margin) versus GRML at $3.51 (N/M Forward P/E, N/A operating margin).

  • Growth vs. Quality Trade-Off: GRML earns the overall head-to-head edge with a stronger Unified Composite Score (56.8/100 HOLD vs. HCTI 36.5/100 SELL) and -5.32β · 95% Vol risk profile, whereas HCTI leads top-line expansion (+158.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: HCTI is currently in a Breakdown options structure phase (RSI 50.6); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HCTI vs GRML
HCTI NASDAQ
Healthcare Triangle, Inc. Common Stock
Services-Computer Integrated Systems Design
$3.42
-6.56% 1D
Market Cap $3.1M
TTM Revenue $26M
Forward P/E N/M
Beta / 30D Vol 10.92β · 6722% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 15.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (148.6% over 20 days), RSI 51
RSI-14: 50.6 · SMA20: $3.94 · SMA50: $1.96
GRML US Equity Head-to-Head Winner
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -5.32β · 95% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.5 · SMA20: $4.67 · SMA50: $6.11

6-Pillar Scorecard Institutional Category Breakdown (HCTI 5 – 1 GRML)

Columns: Metric · HCTI · GRML
1. Valuation Multiples HCTI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale HCTI
Revenue Growth (YoY) +158.4% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $26M N/A
Market Cap $3.1M N/A
3. Profitability & Quality HCTI
Gross Margin 21.5% N/A
Operating Margin -57.4% N/A
Net Profit Margin -66.3% N/A
Return on Equity (ROE) -57.4% N/A
4. Balance Sheet & Cash Flow HCTI
Cash Generation (TTM) -$13M EBITDA N/A
Cash Flow Margin -51.0% EBITDA Mgn N/A
Net Cash / Leverage $6.6M Net Debt (0.21x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GRML
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HCTI
OpEx & R&D Intensity 78.9% of Rev ($20M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HCTI (6) vs GRML (2)
Institutional Metric HCTI GRML Criterion Row Edge
Market Capitalization
Scale
$3.1M N/A Larger Scale HCTI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+158.4% N/A Higher Growth HCTI
Operating Margin (TTM)
Profitability
-57.4% N/A Higher Margin HCTI
Net Profit Margin
Profitability
-66.3% N/A Higher Margin HCTI
Return on Equity (ROE)
Capital Efficiency
-57.4% N/A Higher ROE HCTI
52-Week Range Position
Momentum
33% ($0–$10) 19% ($0–$18) Stronger Trend HCTI
Beta / 30D Volatility
Risk Regime
10.92β · 6722% Vol -5.32β · 95% Vol Lower Realized Risk GRML
Unified Institutional Score
Composite Signal
36.5 / 100 (SELL) 56.8 / 100 (HOLD) Higher Composite GRML
Trailing 12M Revenue (USD)
Operating Scale
$26M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
21.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$13M EBITDA ($6.6M Net Debt (0.21x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HCTI +800.8 pp
HCTI: +759.3% · GRML: -41.5%
3M Horizon GRML +1547.39 pp
HCTI: +219.63% · GRML: +1767.02%
6M Horizon GRML +840.0 pp
HCTI: +54.05% · GRML: +894.05%
1Y Horizon GRML +633.28 pp
HCTI: +16.72% · GRML: +650.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCTI vs GRML. Trailing 12-month operating profitability (HCTI -57.4% vs GRML N/A) and valuation multiples (HCTI N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HCTI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross Margin21.5%
Op. Margin-57.4%
ROE / Fwd P/E-57.4% · N/M
GRML ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HCTI BREAKDOWN
13d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HCTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRML UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GRML Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HCTI Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $3.1M market capitalization and -57.4% operating margin.
OpEx & R&D Reinvestment 78.9% of Rev ($20M)
90D Engineering Disclosures 0 Published
GRML Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HCTI vs GRML Key Questions & Quantitative Answers

As of Nov 16, 2026, GRML (GRML) captures the overall head-to-head institutional edge over Healthcare Triangle, Inc. (HCTI) on higher Unified Composite conviction (56.8/100 HOLD vs. 36.5/100 SELL) after splitting the core matrix 2–6 (led by Options & Positioning), while HCTI wins 5–1 across the 6-pillar growth and valuation breakdown. HCTI trades at $3.42 (N/M Forward P/E, -57.4% operating margin) versus GRML at $3.51 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: GRML earns the overall head-to-head edge with a stronger Unified Composite Score (56.8/100 HOLD vs. HCTI 36.5/100 SELL) and -5.32β · 95% Vol risk profile, whereas HCTI leads top-line expansion (+158.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HCTI is currently in a Breakdown options structure phase (RSI 50.6); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HCTI leads the Growth & Scale pillar: HCTI posts +158.4% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (21.5% gross margin, -57.4% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HCTI generates $26M in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, HCTI deploys 78.9% of Rev ($20M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.

HCTI screens cheaper on headline valuation multiples. HCTI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-51.0% EBITDA margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HCTI (-57.4% ROE) versus GRML (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HCTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (10.92β · 6722% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.